Abbey Diaz
Has grant
Senior Research Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Towards optimal and equitable cardiovascular care pathways for Aboriginal and Torres Strait Islander people with cancer
Open Date: 2022-01-01
Close Date: 2024-12-01
Grant: Close
A feasibility study of an Indigenous patient navigator-led brief health behaviour intervention for Indigenous cancer survivors
Open Date: 2021-11-01
Close Date: 2023-05-01
Grant: Close
UQ Faculty of Medicine 5-year Research Fellowship
Open Date: 2021-10-01
Close Date: 2026-10-01
Grant: Close
Optimising Care: Phase lll Trial in women with metastatic breast cancer to improve quality of life via exercise and diet
Open Date: 2021-01-01
Close Date: 2026-01-01
Grant: Open
Adverse cardiovascular events after cancer: analysis of the NSW 45 and Up cohort
Open Date: 2021-01-01
Close Date: 2032-01-01
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose Cancer significantly impacts First Nations Australians, with higher incidence and lower survival rates. However, understanding of end-of-life (EOL) service use and costs in this population is limited. We aimed to assess EOL healthcare utilisation and costs for First Nations cancer patients in Queensland, Australia. Methods Retrospective data from CancerCostMod, a linked administrative dataset of all cancer diagnoses in Queensland, were used. This dataset includes records from the Queensland Cancer Registry (QCR) from July 1, 2011, to June 30, 2015, linked to Queensland Health Admitted Patient Data Collection (QHAPDC), Emergency Department (ED) Information Systems, Medicare Benefits Schedule (MBS), and Pharmaceutical Benefits Scheme (PBS) data from July 2011 to June 30, 2018. All diagnosed cancer patients who had died during the study period ( N = 467) were included. Health service usage and costs during the last 6 months of life were described and compared across care type, comorbidity status, age group, and residential remoteness using Mann–Whitney and Kruskal–Wallis tests. Results Individuals had at least one hospital episode (100%), ED visit (83%), MBS claim (96%), and PBS claim (96%). The median overall cost per person for hospital episodes was AUD$40,996, with higher costs for those receiving palliative care (AUD$43,521) and chemotherapy (AUD$50,437) compared to those who did not receive these services (palliative: AUD$34,208, chemotherapy: AUD$38,557). Having comorbidities and living in regional and remote areas were associated with higher hospital costs. Conclusion The study findings may guide the re-design and delivery of optimal and culturally appropriate EOL care for First Nations Australians diagnosed with cancer.
Year:
2025
Issue Addressed Lung cancer screening (LCS) is crucial for Indigenous populations due to their higher lung cancer incidence rates and poorer outcomes. Despite efforts to establish LCS programmes, evidence on LCS cost‐effectiveness, participation rates, facilitators and barriers for Indigenous peoples remains limited. This systematic review aims to address this gap by reviewing available evidence. Methods This systematic review conducted searches for relevant articles in PubMed, Scopus, CINAHL, Google Scholar and references/citations of included articles. Results Fifteen out of 19 eligible studies were conducted in the USA, three in New Zealand and one in Canada, with 23 715 Indigenous participants in the 15 quantitative studies. New Zealand studies found that LCS is cost‐effective for Māori, while the participation rate for American Indian/Alaska Natives (4.7%) was lower than for White Americans (21.7%). Facilitators included positive views of LCS, trust in Indigenous‐centred care/providers, trusted invitations, family and community support, transportation or flexible scheduling, culturally competent navigators and detailed health education. Barriers included limited knowledge about LCS/eligibility criteria, fear of the screening process or cancer diagnosis, mistrust or negative experiences in healthcare, cost and time constraints, limited transportation/resources and non‐inclusive eligibility criteria. Conclusions Further research is needed to understand the LCS among Indigenous peoples. Enhancing LCS participation requires leveraging positive experiences and addressing barriers with culturally tailored education and strategic resource allocation. So What? For Australia and similar countries preparing for LCSPs, global evidence highlights the need for adequate resources, integration of Indigenous cultural practices and active involvement of Indigenous communities in programme planning.
Year:
2025
Year:
2025
Year:
2025
The eradication of the commercial tobacco industry is a crucial goal for health and well-being, particularly from a public health and health justice perspective. The term ‘eradication’ is applied in epidemiology to mean the process and outcome of elimination of the—commercial tobacco industry as a human-made—agent of disease and death. In this commentary, we outline why the eradication of the tobacco industry is necessary, urgent and realistic. The potential impact of eradication of the industry is substantial. Without the industry and the commercial tobacco that it produces, it is expected that globally over 22 000 lives will be saved daily (over 8 million annually), and life expectancy will increase. The human right to health underscores the need for tobacco industry accountability for the harms it causes and given the enormous human and financial costs, it is time for action towards eradication of the industry. The tobacco industry’s opposition to tobacco control, particularly strategies focused on market supply and industry reform, has been fierce. Their strategies have involved circumventing, attacking and undermining public health measures to preserve profits. However, with insights learnt from over 70 years of incremental successes in reducing commercial tobacco use, we know that through comprehensive and locally tailored eradication strategies involving legislation, regulation and public health initiatives across multiple levels of governments, we can overcome the resistance from the tobacco industry and their affiliates. Given the cost of commercial tobacco and the ever-growing global consensus on its harms, the time to act is now.
Year:
2025
Objective To quantify costs incurred by the health system for hospital episodes and emergency department (ED) presentations for pancreatic cancer patients within the first three years after diagnosis in Queensland, Australia. Study Settings and Design Using a linked administrative dataset, CancerCostMod, which includes cancer diagnoses from the Queensland Cancer Registry (1st July 2011–30th June 2015) and linked Queensland Health Admitted Patient Data Collection and ED Information Systems records (1st July 2011–30th June 2018), we assessed costs for adults diagnosed with primary pancreatic cancer (International Classification of Diseases, 10th Revision: C25). Costs (in Australian dollars) were assigned using national public costs and private hospital charge datasets for the relevant year. Descriptive analyses were conducted to evaluate hospital and ED utilization and costs. Cost variations across sociodemographic and clinical characteristics were assessed using Kruskal–Wallis or Mann–Whitney U tests. Principal Findings Among 2082 individuals diagnosed with pancreatic cancer, hospital episodes ( n = 26,405) in the first three years after diagnosis cost a total of $100.7 million; median cost per patient was $36,832. For ED presentations ( n = 4228), corresponding figures were $3.6 million (total) and $963 (median per patient). Most of the total hospital (81%) and ED (79%) costs occurred in the first year after diagnosis. Patients who survived ≤ 6 months had the lowest median cost per patient but accounted for 38% of total hospital costs. Median cost per patient varied substantially by socio‐demographic (i.e., Age groups, Indigenous status, socio‐economic disadvantages) and clinical characteristics (i.e., comorbidity, cancer morphology, location of tumor, tumor resection, palliative care). Conclusions Our findings highlight the significant economic burden of pancreatic cancer on the healthcare system, especially within the first year. Targeted strategies are essential to optimize healthcare delivery, ensure equitable access, and improve outcomes.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (21)
Tracey DiSipio
Lecturer
University of Queensland
Jon Emery
Professor of Family Medicine. Director of Research Institute for Cancer Prevention, Screening and Early Detection (RISE)
Nanyang Technological University (NTU)
Neal Palafox
Professor
University of Hawaii
Fiona Stanaway
-
Penney Upton
Associate professor
University of New South Wales (UNSW) - Canberra
Lisa Whop
Associate Professor, National Centre for Aboriginal and Torres Strait Islander Wellbeing Research
Australian National University
Kalinda Griffiths
Director
Flinders University
Michelle Kennedy (Wiradjuri)
University of Newcastle Australia
Roxanne Bainbridge
Deputy Director, Professor
University of Queensland
Raglan Maddox
Australian National University
Katy Bell
Associate Professor of Clinical Epidemiology
University of Sydney
Emma Webster
Associate Professor Rural Research
-
Rohan Telford
Australian National University
Xiang-Yu Hou
University of the Sunshine Coast
Vivienne Milch
Professorial Fellow
Flinders University
Sue Crengle
Professor
University of Otago
Wael Al-Delaimy
University of California, San Diego
Yaqoot Fatima
Professor
University of the Sunshine Coast
Kwun M. Fong
-
Christina Heris
The Australian National University
Gail Garvey
Professor of Indigenous Health Research
University of Queensland
Make your next move.
Prepare your application
Review drafts before you send them.